Clinical trial
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of…
NCT00210483 · Janssen-Ortho LLC, Industry · Completed
Key facts
| NCT number | NCT00210483 |
|---|---|
| Title | A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents |
| Official title | A Randomized, Double-blind, Placebo-controlled Study of Oral Almotriptan Malate (AXERT®) 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents |
| Lead sponsor | Janssen-Ortho LLC, Industry |
| Collaborators | Ortho-McNeil Neurologics, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | almotriptan malate |
| Enrollment | 866 |
| Start date | Jul 1, 2003 |
| Completion | Jul 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: